Cargando…

Hemochromatosis, Erythrocytosis and the JAK2 p.V617F Mutation

Detalles Bibliográficos
Autor principal:	Langabeer, Stephen E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Communications and Publications Division (CPD) of the IFCC 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387703/ https://www.ncbi.nlm.nih.gov/pubmed/28439222

Ejemplares similares

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

The JAK2 V617F mutation in retinal vein or artery occlusion
por: Langabeer, Stephen E.
Publicado: (2019)

Absence of JAK2 V617F-mutated polycythemia vera in obstructive sleep apnea-associated erythrocytosis
por: Langabeer, Stephen E.
Publicado: (2022)

“JAK2 V617F Mutation in Cervical Cancer Related to HPV & STIs” - Letter
por: Langabeer, Stephen E.
Publicado: (2019)

JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera
por: Mori, Naoki, et al.
Publicado: (2023)

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
por: Sugimori, C, et al.
Publicado: (2012)

Screening for Latent Polycythemia Vera in Renal Cell Carcinoma–Associated Erythrocytosis
por: Langabeer, Stephen E.
Publicado: (2023)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

Chronic urticaria reveals JAK2V617F positive essential thrombocythemia
por: Albanesi, Marcello, et al.
Publicado: (2021)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

JAK2 V617F mutation negative erythrocytosis (or how to more simply perform diagnosis and treat a patient with increased hematocrit)
por: Zito, Luca, et al.
Publicado: (2011)

JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines
por: Nauroy, P, et al.
Publicado: (2014)

JAK2 V617F-positive polycythemia vera accompanied by renal artery stenosis
por: Kim, Jae Young, et al.
Publicado: (2014)

Histopathological evaluation of the bone marrow in refractory anemia with ring sideroblasts and thrombocytosis associated to the JAK2-V617F mutation
por: Duarte, Fernando Barroso, et al.
Publicado: (2014)

Simultaneous presentation of JAK2 V617F mutation-related essential thrombocythemia and B-cell chronic lymphocytic leukemia
por: D'Angelo, Guido, et al.
Publicado: (2014)

Clonal Hematopoiesis and JAK2V617F Mutations in Patients With Cardiovascular Disease
por: Yokokawa, Tetsuro, et al.
Publicado: (2021)

Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera
por: Tiong, I S, et al.
Publicado: (2016)

Response to Letter to Editor “JAK2 V617F Mutation in Cervical Cancer Related to HPV & STIs” by Stephen E. Langabeer
por: Sohrabi, Amir
Publicado: (2019)

Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?
por: Kouroupi, E, et al.
Publicado: (2012)

Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis
por: Lim, K-H, et al.
Publicado: (2015)

Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
por: Yi, Jun Ho, et al.
Publicado: (2019)

Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Garbers, Christoph, et al.
Publicado: (2020)

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Genetic analysis of 39 erythrocytosis and hereditary hemochromatosis‐associated genes in the Slovenian family with idiopathic erythrocytosis
por: Kristan, Aleša, et al.
Publicado: (2021)

Low-level somatic JAK2 V617F mutation in myelodysplastic/ myeloproliferative neoplasm with ring sideroblasts, and thrombocytosis with co-mutated SF3B1 and CALR
por: Ji, Young Sok, et al.
Publicado: (2022)

Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation
por: Oka, Satoko, et al.
Publicado: (2017)

Clinical significance of myeloproliferative neoplasms with JAK2V617F mutations and major BCR-ABL1 translocations: a literature review with case presentation
por: Kim, Bohyun, et al.
Publicado: (2020)

Low incidence of EPOR mutations in idiopathic erythrocytosis
por: Filser, Mathilde, et al.
Publicado: (2020)

Analysis of JAK2V617F Tyrosine Kinase Mutation in Blood Donors with Erythrocytosis – A Pilot Study in a Tertiary Care Teaching Hospital of South India
por: Gaddam, Manasa, et al.
Publicado: (2022)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1
por: Gupta, N, et al.
Publicado: (2017)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Hemochromatosis Gene Mutation in Persons Developing Erythrocytosis on Combined Testosterone and SGLT-2 Inhibitor Therapy
por: Schumacher, Kamilya A., et al.
Publicado: (2022)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
por: Zhou, A, et al.
Publicado: (2015)

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing
por: Ferrer-Marín, Francisca, et al.
Publicado: (2013)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Hematopoietic fitness of JAK2(V617F) myeloproliferative neoplasms is linked to clinical outcome
por: Abu-Zeinah, Ghaith, et al.
Publicado: (2022)

Two Cases of Myeloproliferative Neoplasm with a Concurrent JAK2(V617F) Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment
por: Park, Sang Hyuk, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0uhgen768p9okqeids54qfi7o4